Identifying atopic dermatitis patients at risk for conjunctivitis during dupilumab treatment
Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
This study is trying to find out if patients with atopic dermatitis who are treated with dupilumab are more likely to develop conjunctivitis and what factors might contribute to that.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (Utrecht) |
| Trial ID | NCT04276623 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the ophthalmological comorbidities and underlying mechanisms of conjunctivitis in patients with atopic dermatitis who are being treated with dupilumab. Participants will be enrolled in the Bioday Registry to collect data on their experiences and outcomes. The study focuses on understanding how dupilumab treatment may influence the development of conjunctivitis in these patients. By analyzing this data, researchers hope to identify risk factors and improve patient management.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with atopic dermatitis who are indicated for dupilumab treatment and are not currently using oral immunosuppressive medications.
Not a fit: Patients who have received oral or ocular immunosuppressive drugs within two weeks prior to starting dupilumab treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify atopic dermatitis patients at risk for conjunctivitis, leading to better preventive strategies and management.
How similar studies have performed: While this study focuses on a specific aspect of dupilumab treatment, similar studies have shown success in identifying comorbidities in patients with atopic dermatitis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment . Exclusion Criteria: * Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment
Where this trial is running
Utrecht
- University Medical Center Utrecht — Utrecht, Netherlands (Recruiting)
Study contacts
- Study coordinator: Roselie Achten, MD
- Email: r.e.achten@umcutrecht.nl
- Phone: 0031 88 75 57439
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.